Capable
Capable is building a vertically integrated, AI-enabled deeptech platform that designs novel peptide and nucleotide therapeutics and manufactures them through automated solid-phase peptide synthesis. The company aims to compress the drug discovery-to-production pipeline, targeting high-impact medicines in a fraction of traditional timeframes. Its flagship focus is on peptides, a class validated by Tirzepatide's $36B in 2025 sales.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Healthcare Technology
- Manufacturing / Industry 4.0
- Hardware
- Industrial Automation
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Humans are biologically constrained: we are susceptible to major illnesses like cancer and heart disease, and we spend a significant portion of our lives asleep or otherwise limited. Current drug discovery processes are slow and fail to fully leverage frontier AI capabilities, leaving significant human potential and therapeutic opportunities untapped.
Solution
Capable is building a vertically integrated, AI-enabled deeptech platform that combines frontier intelligence with automated polymer synthesis to rapidly explore and unlock new human capabilities. The platform leverages advanced AI models to design novel peptide and nucleotide therapeutics, then uses automated solid-phase peptide synthesis (SPPS) to manufacture these compounds quickly and precisely. By integrating AI-driven design with rapid, automated production, Capable aims to streamline the entire pipeline from computational discovery to physical therapeutic, with the goal of producing the next generation of high-impact drugs in a fraction of the traditional time.
Target Audience
Capable's primary customers are pharmaceutical and biotechnology companies seeking to accelerate peptide- and nucleotide-based drug discovery and development, as well as research institutions focused on expanding human performance and longevity.
Features
- AI-driven therapeutic design platform for discovering novel peptide and nucleotide drug candidates
- Automated solid-phase peptide synthesis (SPPS) enabling rapid, scalable polymer production
- Vertically integrated workflow that connects AI models directly to physical synthesis and testing
- Focus on peptide therapeutics, a class validated by top-selling drugs such as Tirzepatide, which generated $36B in 2025 sales
- Deeptech infrastructure designed to unlock new human capabilities beyond treating disease, including ambitions like more energy on less sleep